NSE: A Promising Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: NEIL3

NCBI ID: G55247

NEIL3

NSE: A Promising Drug Target and Biomarker for Neurodegenerative Diseases

Neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's have a significant impact on the lives of millions of people worldwide. These conditions are characterized by the progressive loss of brain cells, leading to a wide range of symptoms such as memory loss, cognitive decline, and behavioral changes. Despite advances in treatment, there is currently no cure for these diseases, and researchers are constantly searching for new drug targets or biomarkers to improve treatment outcomes.

One potential drug target that has received a lot of attention in recent years is Neuron-Specific Extraction of Lipids (NSE), also known as NEIL3. NSE is a technique that involves the extraction of specific lipids from the brain, which can be used to study the structure and function of brain cells. This technique has been used to study a wide range of brain regions, including the frontal cortex, entorhinal cortex, and cerebellum, and has provided new insights into the biology of these regions.

One of the reasons why NSE has generated so much interest is its potential as a drug target. The brain contains a large number of lipids, which are an essential component of brain cells. These lipids play a crucial role in maintaining the structural and functional integrity of brain cells, and are also involved in the production of various signaling molecules that are important for brain function.

One of the key features of NSE is its selectivity for certain types of lipids. NSE has been shown to be particularly effective at extracting the phospholipid phosphatidylcholine (PC) from the brain, which is a major component of the cell membrane and is involved in various signaling pathways. PC is also a key component of the neurotransmitter acetylcholine, which is involved in memory and cognitive function.

In addition to its potential as a drug target, NSE has also been shown to have a number of potential applications in research. For example, NSE has been used to study the effects of various drugs on brain function, including those that are designed to treat neurodegenerative diseases. This has allowed researchers to gain a better understanding of the underlying mechanisms of these drugs and has helped to identify new potential drug targets.

Another potential application of NSE is its use as a biomarker for neurodegenerative diseases. Because NSE is specific for the PC lipid, it has been shown to be a reliable biomarker for the diagnosis of certain types of neurodegenerative diseases, such as Alzheimer's and Parkinson's. This has led to the potential for NSE to be used as a diagnostic tool, in addition to a drug target.

While NSE is still in the early stages of research, it has already generated a lot of interest among researchers due to its potential as a drug target and biomarker. Further studies are needed to fully understand the role of NSE in neurodegenerative diseases and to determine its safety and effectiveness as a potential drug.

Protein Name: Nei Like DNA Glycosylase 3

Functions: DNA glycosylase which prefers single-stranded DNA (ssDNA), or partially ssDNA structures such as bubble and fork structures, to double-stranded DNA (dsDNA) (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964). Mediates interstrand cross-link repair in response to replication stress: acts by mediating DNA glycosylase activity, cleaving one of the two N-glycosyl bonds comprising the interstrand cross-link, which avoids the formation of a double-strand break but generates an abasic site that is bypassed by translesion synthesis polymerases (By similarity). In vitro, displays strong glycosylase activity towards the hydantoin lesions spiroiminodihydantoin (Sp) and guanidinohydantoin (Gh) in both ssDNA and dsDNA; also recognizes FapyA, FapyG, 5-OHU, 5-OHC, 5-OHMH, Tg and 8-oxoA lesions in ssDNA (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964). No activity on 8-oxoG detected (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964). Also shows weak DNA-(apurinic or apyrimidinic site) lyase activity (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964). In vivo, appears to be the primary enzyme involved in removing Sp and Gh from ssDNA in neonatal tissues (PubMed:12433996, PubMed:19170771, PubMed:22569481, PubMed:23755964)

The "NEIL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEIL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets